Schedule of Convertible Note Payable |
Convertible note payable consists of the following
at March 31, 2020 and December 31, 2019, respectively:
|
|
March 31,
2020 |
|
|
December 31,
2019 |
|
|
|
|
|
|
|
|
On November 30, 2018, the Company received proceeds of $300,000 on a secured convertible note that carries a 6% interest rate from CSW Ventures, LP (“CSW”). The proceeds were used to fund the Company’s purchase of 875,000 shares of common stock, on a 1:4 split adjusted basis, of One World Pharma, Inc. The Note is due on demand. In the event that the Company consummated the closing of a public or private offering of its equity securities, resulting in gross proceeds of at least $500,000 (“Qualified Financing”) at any time prior to the repayment of this note, then the outstanding principal and unpaid interest may, at the option of the holder, be converted into such equity securities at a conversion price equal to eighty percent (80%) of the purchase price paid by the investors purchasing the equity securities in the Qualified Financing. A Qualified Financing subsequently occurred on February 4, 2019, at which time the convertible note became convertible at a fixed conversion price of $0.40 per share. The Company’s obligations under this Note are secured by a lien on the assets of the Company. |
|
$ |
300,000 |
|
|
$ |
300,000 |
|
|
|
|
|
|
|
|
|
|
On July 22, 2019, a total of $207,332, consisting of $200,000 of principal and $7,332 of unpaid interest, on two outstanding demand notes owed to CSW that originated on November 26, 2018 and December 26, 2018, were exchanged for a convertible promissory note in the principal amount of $207,332, due on demand (the “Second Convertible CSW Note”). The Second Convertible CSW Note bears interest at 6% per annum and is convertible at the option of the holder into shares of common stock at a price of $0.50 per share. |
|
|
207,332 |
|
|
|
207,332 |
|
Less: unamortized debt discounts |
|
|
- |
|
|
|
- |
|
Convertible note payable |
|
$ |
507,332 |
|
|
$ |
507,332 |
|
|